Nota AI Showcases Generative AI-Based Next-Gen Traffic Innovation at ITSWC 2025, Demonstrating Leadership on the Global Stage

• Successful U.S. PoC with Sony underscores accelerated global market expansion
• Joint showcases with Korea Pavilion, hosted by MOLIT•LG CNS highlight Korea's leadership and the global competitiveness of ITS technology

SEOUL, South Korea, Aug. 29, 2025 /PRNewswire/ -- Nota AI (CEO Myungsu Chae), a company specializing in AI model compression and optimization, announced the successful conclusion of its participation at the ITS World Congress 2025 (ITSWC 2025), held in Atlanta, Georgia, from August 24 to 28.  Recognized as the world's largest event dedicated to Intelligent Transport Systems (ITS), the Congress brought together more than 15,000 attendees and 200 companies from around the globe.

At this exhibition, Nota AI operated joint booths at the Korea Pavilion, hosted by the Ministry of Land, Infrastructure and Transport (MOLIT) and the LG CNS booth, while also showcasing the results of its collaboration with Sony. The company focused on highlighting the global competitiveness of its generative AI-based ITS technologies, powered by its proprietary Vision-Language Model (VLM).

At the Korea Pavilion, hosted by MOLIT, Nota AI showcased its generative AI-based intelligent incident detection system. Developed independently by Nota AI, this technology uses a VLM to detect various hazardous situations such as traffic accidents, fires, and road obstacles in real time. Additionally, it analyzes the correlation between events to minimize unnecessary alarms during incident detection, making it a next-generation control technology that captures the attention of visitors.

In the LG CNS booth, Nota AI presented its AI-powered intelligent traffic management solutions, which received significant attention from international visitors. The solution analyzes the movement of key objects such as vehicles and pedestrians on roads and in ports, quickly sending alerts during emergencies. The system also enhances operational efficiency and safety and facilitates real-time communication with various agents through V2X communication.

Additionally, Nota AI showcased its excellent technical capabilities by revealing the successful PoC results conducted in Lakewood, U.S., in collaboration with Sony. The project focused on verifying the potential for pedestrian safety management and traffic volume analysis in a specific area known for frequent jaywalking accidents. Nota AI's proprietary AI optimization technology was applied to cameras equipped with Sony's IMX500 smart image sensor, achieving a 100% accuracy in the verification process.

"ITS World Congress 2025 was a pivotal opportunity to demonstrate the global competitiveness of our generative AI-based ITS solutions, built on both domestic and international partnerships. Moving forward, we will continue to strengthen our global presence and lead the future of smart city traffic management and mobility innovation." said Myungsu Chae, CEO of Nota AI.

Nota AI's leadership in ITS has been validated by both technical performance and global commercialization. In Korea, the company's ITS solution received the highest rating in the Ministry of Land, Infrastructure and Transport's Smart Intersection System performance evaluation, achieving more than 99% accuracy. In April, Nota AI became the first Korean company to successfully commercialize generative AI-based ITS solutions in the Middle East through a supply agreement with the Dubai Roads and Transport Authority (RTA).

Nota AI plans to showcase these business achievements at the upcoming 2026 Gangneung ITS World Congress, aiming to build a successful congress and expand its global network. Additionally, the company was recently selected as a final member of the Ministry of Science and ICT's "National AI" project, advancing the development of its proprietary foundation models. In August, Nota AI also filed its securities registration statement, with plans to complete its KOSDAQ listing by the end of the year.

SEOUL, South Korea, Aug. 29, 2025 /PRNewswire/ -- Nota AI (CEO Myungsu Chae), a company specializing in AI model compression and optimization, announced the successful conclusion of its participation at the ITS World Congress 2025 (ITSWC 2025), held in Atlanta, Georgia, from August 24 to 28.  Recognized as the world's largest event dedicated to Intelligent Transport Systems (ITS), the Congress brought together more than 15,000 attendees and 200 companies from around the globe.

At this exhibition, Nota AI operated joint booths at the Korea Pavilion, hosted by the Ministry of Land, Infrastructure and Transport (MOLIT) and the LG CNS booth, while also showcasing the results of its collaboration with Sony. The company focused on highlighting the global competitiveness of its generative AI-based ITS technologies, powered by its proprietary Vision-Language Model (VLM).

At the Korea Pavilion, hosted by MOLIT, Nota AI showcased its generative AI-based intelligent incident detection system. Developed independently by Nota AI, this technology uses a VLM to detect various hazardous situations such as traffic accidents, fires, and road obstacles in real time. Additionally, it analyzes the correlation between events to minimize unnecessary alarms during incident detection, making it a next-generation control technology that captures the attention of visitors.

In the LG CNS booth, Nota AI presented its AI-powered intelligent traffic management solutions, which received significant attention from international visitors. The solution analyzes the movement of key objects such as vehicles and pedestrians on roads and in ports, quickly sending alerts during emergencies. The system also enhances operational efficiency and safety and facilitates real-time communication with various agents through V2X communication.

Additionally, Nota AI showcased its excellent technical capabilities by revealing the successful PoC results conducted in Lakewood, U.S., in collaboration with Sony. The project focused on verifying the potential for pedestrian safety management and traffic volume analysis in a specific area known for frequent jaywalking accidents. Nota AI's proprietary AI optimization technology was applied to cameras equipped with Sony's IMX500 smart image sensor, achieving a 100% accuracy in the verification process.

"ITS World Congress 2025 was a pivotal opportunity to demonstrate the global competitiveness of our generative AI-based ITS solutions, built on both domestic and international partnerships. Moving forward, we will continue to strengthen our global presence and lead the future of smart city traffic management and mobility innovation." said Myungsu Chae, CEO of Nota AI.

Nota AI's leadership in ITS has been validated by both technical performance and global commercialization. In Korea, the company's ITS solution received the highest rating in the Ministry of Land, Infrastructure and Transport's Smart Intersection System performance evaluation, achieving more than 99% accuracy. In April, Nota AI became the first Korean company to successfully commercialize generative AI-based ITS solutions in the Middle East through a supply agreement with the Dubai Roads and Transport Authority (RTA).

Nota AI plans to showcase these business achievements at the upcoming 2026 Gangneung ITS World Congress, aiming to build a successful congress and expand its global network. Additionally, the company was recently selected as a final member of the Ministry of Science and ICT's "National AI" project, advancing the development of its proprietary foundation models. In August, Nota AI also filed its securities registration statement, with plans to complete its KOSDAQ listing by the end of the year.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Nota AI Showcases Generative AI-Based Next-Gen Traffic Innovation at ITSWC 2025, Demonstrating Leadership on the Global Stage

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 at the 14th World Congress for Hair Research (WCHR) in Seoul, South Korea. The results were presented orally by Professor Cheng Zhou, Director of the Department of Dermatology at Peking University People's Hospital.

CG2001 is a topical fixed-dose combination formulation containing minoxidil and finasteride, being evaluated for the treatment of male androgenetic alopecia.

The trial consisted of the following treatment arms: CG2001 (5% Minoxidil and 0.075% Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.1% Finasteride) once daily (QD); CG2001 (5% Minoxidil and 0.075% Finasteride) twice daily (BID); and a Control Group.

The study met its primary endpoint: at Week 24, the group treated with CG2001 (5% Minoxidil and 0.075% Finasteride) twice daily demonstrated a statistically significant improvement in the change from baseline in Target Area Hair Count (TAHC) compared to the placebo group. Additionally, favorable safety and tolerability results were observed.

Key topline results include:

• At Week 24, the group treated with CG2001 (5% Minoxidil and 0.075% Finasteride) twice daily achieved an increase of 28.17 hairs/cm² from baseline in TAHC (p=0.006), a key efficacy metric, outperforming the placebo group, which showed an increase of 7.68 hairs/cm².
• In the CG2001 (Minoxidil 5% and Finasteride 0.075%) twice-daily group, a trend of sustained increase in ΔTAHC was observed at Weeks 6, 12, 18, and 24.
• In the CG2001 (Minoxidil 5% and Finasteride 0.075%) twice-daily group a trend toward improvement in subject self-assessments, were also observed.
• CG2001 was generally well-tolerated across all treatment groups, and no sex related adverse event were identified.
• All adverse events were mild to moderate in severity.

"Despite approved treatment options, androgenetic alopecia remains an area of significant unmet medical need. We are encouraged by the Phase II results, which support CG2001's potential as a differentiated treatment option and its continued clinical development," said Baohui Yu, CEO of Dayspring Pharma.

Dayspring Pharma is currently engaging with regulatory authorities to define the next phase of clinical development.

About CG2001
CG2001 is a topical combination of minoxidil and finasteride developed to harness the synergistic potential of two cornerstone therapies for AGA. Both are widely recognized as first-line treatments for male pattern hair loss: minoxidil promotes hair growth, while finasteride inhibits 5α-reductase and reduces dihydrotestosterone levels.

CG2001 is formulated as a specifically designed foam with an optimized dose ratio and delivery system to improve local follicular delivery, enhance efficacy, and minimize systemic exposure associated with oral finasteride.

About Dayspring Pharma

Dayspring Pharma is a pharmaceutical company focused on innovation in dermatology and hair health. The company develops differentiated therapies to address unmet clinical needs. For more information, please visit dayspringpharma.com.

Contact: Dayspring Pharma, chenguang@dayspringpharma.com 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)